1. 2019
  2. Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma

    Seremet, T., Planken, S., Schwarze, J. K., Jansen, Y., Vandeweerd, L., van den Begin, R., Tsechelidis, I., Lienard, D., Del Marmol, V. & Neyns, B., Feb 2019, In : Melanoma Research. 29, 1, p. 85-88 4 p.

    Research output: Contribution to journalArticle

  3. Emotional disturbances, social outcome and neurocognitive function in advanced melanoma survivors treated with pembrolizumab

    Rogiers, A., De Cremer, J., Awada, G., Schwarze, J. K., Ben Salama, L., Theuns, P., De Ridder, M. & Neyns, B., 15 Jan 2019, In : Journal of Translational Medicine. 17, S1, 07.

    Research output: Contribution to journalMeeting abstract (Journal)

  4. Supportieve zorg bij de behandeling met immuuncheckpointinhibitoren

    Awada, G., Rogiers, A. I. & Neyns, B., 9 Jan 2019, In : OncoHemato. 12, 7, p. 39-50

    Research output: Contribution to journalArticle

  5. An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

    Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 others, Rutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

    Research output: Contribution to journalArticle

  6. Cancer-associated cachexia, reactive oxygen species, and nutrition therapy

    Bjorklund, G., Dadar, M., Aaseth, J., Chirumbolo, S. & Pen, J. J., 2019, In : Current Medicinal Chemistry. 26, 31, p. 5728-5744 17 p.

    Research output: Contribution to journalArticle

  7. Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery

    Quinten, C., Kenis, C., Decoster, L., Debruyne, P. R., De Groof, I., Focan, C., Cornelis, F., Verschaeve, V., Bachmann, C., Bron, D., Luce, S., Debugne, G., Van den Bulck, H., Goeminne, J. C., Baitar, A., Geboers, K., Petit, B., Langenaeken, C., Van Rijswijk, R., Specenier, P. & 8 others, Jerusalem, G., Praet, J. P., Vandenborre, K., Lycke, M., Flamaing, J., Milisen, K., Lobelle, J. P. & Wildiers, H., 2019, In : Quality of Life Research. 28, 3, p. 663-676 14 p.

    Research output: Contribution to journalArticle

  8. Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?

    Remon, J., Hendriks, L., Aspeslagh, S. & Besse, B., 2019, In : Journal of Thoracic Oncology. 14, 10, p. 1701-1703 3 p.

    Research output: Contribution to journalComment/debate

  9. On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients

    Verbaanderd, C., Rooman, I., Meheus, L. & Huys, I., 2019, In : Frontiers in Pharmacology. 10, 1664.

    Research output: Contribution to journalArticle

Previous 1...4 5 6 7 8 9 10 11 ...57 Next

ID: 25692